Streetbeat News

Equity Actions

CHTR

Charter Communications (CHTR) reported an increase in capital expenditures from $9.4 billion in 2022 to $11.1 billion in 2023, driven by its rural construction initiative and network expansion. The company anticipates further increasing its capex to between $12.2 billion and $12.4 billion in 2024, with significant investments in line extensions and network evolution.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:42 pm

CATX

EXFY

PCSA

RVP

Insiders are buying shares in four US-listed companies under $3: Retractable Technologies, Expensify, Perspective Therapeutics, and Processa Pharmaceuticals. These transactions indicate insider confidence in the companies' prospects. Retractable Technologies reported a loss, while Expensify received a price target upgrade. Perspective Therapeutics signed a licensing agreement, and Processa Pharmaceuticals announced a public offering.

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 12:09 pm

BP

Kate Thomson has been officially appointed as the Chief Financial Officer (CFO) of BP and has joined the company's board with immediate effect. She has served as the interim CFO since September 2023.

Portfolio Pulse from Charles Gross

February 02, 2024 | 12:07 pm

HOLX

Analyst ratings for Hologic (NASDAQ:HOLX) show mixed sentiments with a recent shift towards bullishness. The average 12-month price target is now $80.5, down from $83.50. Analysts from Needham, UBS, Morgan Stanley, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market dynamics and Hologic's performance. Hologic, focusing on women's healthcare, faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 12:00 pm

META

Meta Platforms, Inc. (NASDAQ:META) shares surged over 16% in premarket trading following its Q4 earnings report, which exceeded expectations and surpassed Wall Street forecasts for key user metrics. The company also announced a quarterly dividend of 50 cents per share and a new $50 billion share repurchase authorization. KeyBanc Capital Markets analyst Justin Patterson reiterated an Overweight rating and increased the price target from $465 to $575, citing strong capital allocation and atypically strong 1Q guidance.

Portfolio Pulse from Shanthi Rexaline

February 02, 2024 | 10:46 am

HCM

HUTCHMED (China) Limited announced that Inmagene Biopharmaceuticals has exercised options to license two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership. HUTCHMED will receive approximately 7.5% of Inmagene's fully diluted shares in return for granting an exclusive license to Inmagene for the development, manufacturing, and commercialization of these candidates worldwide.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 8:35 am

AAPL

AMZN

BMY

META

XOM

U.S. stock futures are trading higher with focus on Exxon Mobil, Apple, Bristol-Myers Squibb, Amazon, and Meta Platforms ahead of Friday. Exxon Mobil is expected to report earnings of $2.21 per share. Apple reported higher than expected earnings but saw a revenue decline in China. Bristol-Myers Squibb is anticipated to earn $1.53 per share. Amazon reported strong results and provided optimistic revenue and operating income guidance. Meta Platforms announced positive financial results, a new dividend, and a $50 billion share repurchase authorization.

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 8:20 am

RKLB

Rocket Lab has upsized its offering of convertible senior notes to $300M at a 4.250% interest rate, maturing in 2029. The initial offering was increased from $275M, with an option for purchasers to buy an additional $55M within 13 days of issuance. The offering is set to close on February 6, 2024, with interest payments starting August 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 7:05 am

ANRO

Alto Neuroscience, Inc. (ANRO) has announced the pricing of its upsized initial public offering (IPO) of 8.04 million shares at $16 per share, aiming to raise approximately $128.6 million before expenses. Additionally, underwriters have a 30-day option to purchase up to 1.206 million more shares at the IPO price, less discounts and commissions.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 7:03 am

GUTS

Fractyl Health has announced the pricing of its initial public offering (IPO) of 7,333,333 common shares at $15 per share, aiming to raise approximately $110 million. The offering is set to close on February 6, 2024, with an option for underwriters to purchase up to an additional 1,099,999 shares. The IPO's success could signal investor confidence in Fractyl Health's market potential.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 6:30 am